Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic

H. Moualla, D. A. Mills, R. Hromas, C. F. Verschraegen

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


(Chemical Equation Presented) Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharma for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II, causing replication-dependent DNA damage in the S-phase of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemia (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.

Original languageEnglish (US)
Pages (from-to)363-374
Number of pages12
JournalDrugs of the Future
Issue number5
StatePublished - May 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic'. Together they form a unique fingerprint.

Cite this